Oppenheimer raised the firm’s price target on Amrize (AMRZ) to $70 from $64 and keeps an Outperform rating on the shares. The firm notes shares jumped after Amrize reported Q4 2025 EBITDA of $779M and guided 2026 revenue and profitability moderately above Street outlook.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRZ:
- Amrize price target raised to $66 from $59 at Wells Fargo
- Amrize price target raised to $70 from $64 at Berenberg
- Amrize Expands West Texas Footprint With Acquisition of PB Materials
- Amrize Files 2025 Form 10-K, Highlighting $11.8 Billion in Revenue and North American Scale
- Amrize Boosts Cash Returns as Infrastructure Demand Fuels 2025 Results